Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 4/20 | 0.55 |
| ▸ | MAOB | P27338 | 4/20 | 0.55 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.37 |
| ▸ | BAD | Q92934 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20146334 | 0.80 | GSK3B (0.45) | PTPN1MAOAMAOB | |
| SCHEMBL12318444 | 0.78 | PTPN1 (0.54) | PTPN1NPC1RAB9ACA1CA2 | |
| SCHEMBL26121122 | 0.78 | MAOA (0.57) | PTPN1MAOAMAOBCES2CES1 | |
| SCHEMBL2297994 | 0.78 | GSK3B (0.54) | MAOAMAOBCES2CES1CA1 | |
| SCHEMBL7009925 | 0.77 | MAOA (0.47) | PTPN1MAOAMAOBCES2CES1 | |
| SCHEMBL991358 | 0.76 | GSK3B (0.56) | MAOAMAOBCES2CES1CA1 | |
| SCHEMBL10413993 | 0.76 | MAOA (0.55) | PTPN1MAOAMAOBCES2CES1 | |
| SCHEMBL989952 | 0.76 | CES2 (0.48) | PTPN1MAOAMAOBCES2CES1 | |
| SCHEMBL250821 | 0.75 | PTPN1 (0.52) | PTPN1MAOAMAOBCES2CES1 | |
| SCHEMBL20716158 | 0.73 | ALDH1A1 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3433239-B1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2026-05-27 | — | — | EP | disclosed |
| US-11766433-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-09-26 | — | — | US | disclosed |
| US-11766433-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-09-26 | — | — | US | disclosed |
| US-11766433-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-09-26 | — | — | US | disclosed |
| EP-3844161-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2021-07-07 | — | — | EP | disclosed |
| US-20210186963-A1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-06-24 | — | — | US | disclosed |
| US-10980806-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2021-04-20 | — | — | US | disclosed |
| WO-2020043658-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-03-05 | — | — | WO | disclosed |
| EP-3433239-A1 | SMALL MOLECULE INHIBITOR OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | University of Pittsburgh- Of the Commonwealth System of Higher Education (US) | 2019-01-30 | — | — | EP | disclosed |
| US-20190022093-A1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2019-01-24 | — | — | US | disclosed |
| US-20130210803-A1 | FUSED TETRACYCLIC PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2013-08-15 | — | — | US | disclosed |
| WO-2011103460-A1 | FUSED TETRACYCLIC PYRIDO[4,3-B]INDOLE AND PYRIDO[3,4-B]ONDOLE DERIVATIVES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011103485-A1 | FUSED TETRACYCLIC PYRIDO[4,3-B]INDOLE AND PYRIDO[3,4-B]INDOLE DERIVATIVES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011103485-A1 | FUSED TETRACYCLIC PYRIDO[4,3-B]INDOLE AND PYRIDO[3,4-B]INDOLE DERIVATIVES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| EP-2346332-A1 | PYRIDO (4,3-B) INDOLES CONTAINING RIGID MOIETIES | Medivation Technologies, Inc. (US) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010051501-A1 | PYRIDO (4,3-B) INDOLES CONTAINING RIGID MOIETIES | MEDIVATION TECHNOLOGIES, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
| WO-2006094201-A2 | SEMICARBAZIDE-SENSITIVE AMIDE OXIDASE INHIBITORS | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2006-09-08 | — | — | WO | disclosed |
| EP-1663954-A2 | INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT OF DISEASES | LA JOLLA PHARMACEUTICAL CO. (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050096360-A1 | Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment of diseases | LA JOLLA PHARMACEUTICALS COMPANY | 2005-05-05 | — | — | US | disclosed |
| WO-2005014530-A2 | INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT OF DISEASES | LA JOLLA PHARMACEUTICAL CO. (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210186963-A1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | AR, NR0B1, NCOA3 | PTPN1 2304/4885MAOA 3271/4885MAOB 1448/4885 |
| US-20190022093-A1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | AR, NR0B1, NCOA3 | PTPN1 2230/4885MAOA 3604/4885MAOB 1952/4885 |
| US-20130210803-A1 | FUSED TETRACYCLIC PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | HTR4, HTR3B, HTR2C | PTPN1 2181/4885MAOA 55/4885MAOB 22/4885 |
| US-20050096360-A1 | Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment of diseases | VCAM1, AOC2, AOC3 | PTPN1 3907/4885MAOA 74/4885MAOB 71/4885 |
| US-11766433-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | AR, NR0B1, NCOA3 | PTPN1 2244/4885MAOA 3574/4885MAOB 1729/4885 |
| US-10980806-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | AR, NR0B1, NCOA3 | PTPN1 2244/4885MAOA 3574/4885MAOB 1729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.